Pharma News
27 Jul 2025 to 02 Aug 2025
Aug 2, 2025
German court invalidates Bayer's patent for Xarelto | Europe
Bayer is engaged in a 27-country litigation effort to safeguard its blockbuster blood thinner from generic competition, with billions in revenue at stake. Marisa Woutersen reports that Bayer's external litigation counsel is prepared for any challenges that may arise.
Aug 2, 2025
AIDS advocates file a lawsuit against HHS to access Gilead's settlement regarding patents for HIV prevention medications.
A patient advocacy group is suing the Trump administration for not disclosing details of a settlement with Gilead Sciences regarding patent rights to HIV prevention pills Truvada and Descovy. The case highlights concerns over government-funded research and the high prices charged by Gilead, amid ongoing debates about prescription drug costs in the U.S.
Aug 2, 2025
Dr. Reddy's Lab Prepares to Introduce Generic Obesity Medication, Anticipating Significant Revenue Boost
Dr Reddy’s Laboratories is set to launch a generic version of Novo Nordisk’s obesity drug, Wegovy, in 87 countries next year, targeting emerging markets. With semaglutide patents expiring, the obesity drug market is projected to reach $150 billion by the early 2030s. Patent disputes are ongoing, as Novo Nordisk has sued Dr Reddy’s for infringement.
Aug 2, 2025
Medicenna enhances its intellectual property portfolio by securing five patents for its IL-2 and IL-4 Superkines.
Medicenna Therapeutics Corp. has secured five new patents for its IL-2 and IL-4 Superkine platforms, enhancing its intellectual property across key markets. Notable patents include coverage for IL-2 superagonists combined with anti-PD-1 antibodies and an IL-4 formulation for CNS tumors. These patents bolster Medicenna's clinical programs and support its ongoing phase 1/2 ABILITY-1 study and phase 2b trial for MDNA55.
Aug 2, 2025
Key Findings from Health Canada's Statistical Report on Canadian Pharmaceuticals for 2024-2025
Health Canada's 2024-2025 Statistical Report reveals a decline in patent-related activity, with 33 generic/biosimilar litigation actions filed, down from 39 the previous year. The number of biosimilar/generic submissions rose to 115. Patent lists dropped to 900, and 32 human drugs were added to the Register of Innovative Drugs. The Certificates of Supplementary Protection regime saw 11 applications filed.
Aug 2, 2025
Trump calls on leading pharmaceutical companies to reduce prescription drug prices in the U.S. | TechTarget
President Trump has sent letters to 17 major drug companies, including Pfizer, Merck, and Johnson & Johnson, demanding they adopt "most favored nation" pricing to lower prescription drug costs. Companies must comply by September 29 or face federal action. Trump criticized previous proposals from the industry, insisting on immediate relief for American families from inflated drug prices.
Aug 1, 2025
Xanax's parent company defends against the 'Canvax' trademark in the European Union - Life Sciences Intellectual Property Review
US customs authorities have confiscated tens of thousands of counterfeit and unapproved COVID-19 test kits, primarily shipped via the postal system, since the pandemic began.
Aug 1, 2025
Metacel Pharmaceuticals, LLC vs. Rubicon Research Private Limited | Robins Kaplan LLP - JDSupra
The Federal Circuit affirmed a district court ruling favoring Rubicon Research in a patent infringement case involving Ozobax® (baclofen). Metacel Pharmaceuticals alleged that Rubicon's proposed label for its generic baclofen would induce infringement of U.S. Patent No. 10,610,502. The court found that the label merely permitted, but did not instruct, infringing use, thus ruling in favor of Rubicon.
Aug 1, 2025
Beijing Tide Pharmaceutical discovers nanobody-drug conjugates aimed at treating lung cancer | BioWorld
Beijing Tide Pharmaceutical Co. Ltd. has announced the development of nanobody-drug conjugates targeting B7 homolog 3 (B7-H3, CD276) linked to exatecan, aimed at treating lung cancer.
Aug 1, 2025
MAIN NEWS: Dr. Magoola of Dei BioPharma submits fresh US patent applications for innovative cancer treatments...
Dei BioPharma, an African biotech firm, has received patent acceptance from the USPTO for two innovative therapeutic platforms. One is a universal mRNA cancer vaccine that transforms immune-invisible tumors into responsive targets, showing remarkable efficacy. The second is a cost-efficient scFv biologic targeting IL-23p19, offering multiple administration routes and reducing production costs by 80%.
Aug 1, 2025
Exploitation in HIV Medication Pricing and Worldwide Disparities - Peoples Democracy
The UK's NHS has approved Hemgenix, a gene therapy for hemophilia B, costing £2.6 million, making it the world's most expensive medicine. Developed by uniQure and commercialized by CSL Behring, the approval highlights issues of drug pricing and access. Meanwhile, Gilead Sciences' Lenacapavir for HIV treatment is criticized for its high cost, despite potential for affordable production.
Aug 1, 2025
Bayer's Pharma Sector: A Strong Growth Narrative for 2025 - AInvest
Bayer's Pharmaceuticals Division is thriving in 2025, driven by blockbuster drugs Kerendia and Nubeqa, which saw significant sales increases. The company is also advancing a robust R&D pipeline, including therapies for cancer and neurology. With effective cost management and strong margins, Bayer is positioned for double-digit EBITDA growth, making it a compelling investment opportunity.
Aug 1, 2025
3 Healthcare Stocks Offering Dividends Worth Investing In Before They Surge | The Motley Fool
Eli Lilly, AbbVie, and Pfizer are highlighted as strong dividend healthcare stocks for long-term investment. Eli Lilly (LLY) benefits from its GLP-1 drugs Mounjaro and Zepbound, while AbbVie (ABBV) sees growth from Skyrizi and Rinvoq. Pfizer (PFE) offers a high yield of 7% despite challenges from declining COVID-19 product sales and upcoming patent expirations.
Aug 1, 2025
3 Healthcare Stocks Offering Dividends Worth Investing in Before Their Value Increases Significantly - Mitrade
Eli Lilly is at the forefront of the GLP-1 weight-loss market with its drugs Mounjaro and Zepbound, while AbbVie is adapting post-Humira with strong growth from Skyrizi and Rinvoq. Pfizer faces challenges from declining COVID-19 product sales but is bolstering its oncology pipeline through acquisitions. All three companies remain solid long-term investment options.
Aug 1, 2025
Bristol-Myers Squibb Experiences 197.82% Increase in Trading Volume, Reaching $1.95 Billion and Ranking 51st - AInvest
Bristol-Myers Squibb (BMY) reported a trading volume surge of 197.82% on July 31, 2025, despite a 5.81% stock decline. Q2 2025 revenue reached $12.3 billion, driven by Eliquis and Opdivo. However, concerns over growth strategies and rising expenses persist, alongside a $570 million charge related to a BioNTech partnership. Revlimid sales projections were raised amid competitive risks.
Aug 1, 2025
Teva resolves dispute over asthma inhalers with American competitor | Americas
Teva Pharmaceuticals has raised concerns over a panel's narrow interpretation of "claims the drug," warning it could significantly impact the Orange Book and reshape patent listing standards. The stay granted while an en banc rehearing is considered may influence the availability of generic drugs in the market.
Aug 1, 2025
Lilly's Mounjaro Shows Promising Results in Cardiovascular Study, Plans to Pursue Broader Approval - BioSpace
Eli Lilly's diabetes drug Mounjaro (tirzepatide) showed promising results in a Phase III trial, reducing cardiovascular risks by 8% compared to Trulicity but did not achieve statistical superiority. Mounjaro demonstrated a 16% lower all-cause mortality rate and greater A1C reduction. Lilly plans to submit the data to regulators by year-end, as it continues to report strong revenue growth.
Jul 31, 2025
Weight-loss medications have been approved for use in India, but there are some conditions - NewsBytes
India has legalized weight-loss drugs, including Mounjaro and Wegovy, marking a significant shift in obesity treatment. These medications, previously smuggled, are now widely available, particularly in cities like Delhi, where Type 2 diabetes is prevalent. Demand for these drugs has surged fivefold since 2021 as individuals seek effective weight-loss solutions.
Jul 31, 2025
Simcere Zaiming Pharmaceutical unveils novel antibody-drug conjugates - BioWorld
Simcere Zaiming Pharmaceutical Co. Ltd. has unveiled new antibody-drug conjugates (ADCs) that utilize human monoclonal antibodies targeting the zinc transporter ZIP6 (SLC39A6; LIV-1). These ADCs are covalently linked to cytotoxic drugs and are reported to be beneficial for cancer treatment.
Jul 31, 2025
Eli Lilly's Mounjaro demonstrates comparable cardiovascular advantages to Trulicity - CNBC
Eli Lilly's Mounjaro demonstrated significant heart health benefits in a trial compared to Trulicity, showing a 16% lower death rate and an 8% reduced risk of cardiovascular events in Type 2 diabetes patients. Despite these findings, analysts suggest the results may not significantly shift prescribing habits. Eli Lilly plans to submit the data for regulatory approval by year-end.
Jul 31, 2025
What is the Future Outlook for Pfizer (PFE) Over the Next Five Years?
Pfizer (NYSE: PFE) is expected to shift its focus towards oncology by 2030, with new top-selling drugs replacing current blockbusters like Eliquis and Ibrance. The company aims for operational efficiencies, projecting $4.5 billion in savings, and remains committed to its dividend program. Despite recent setbacks, Pfizer's market cap could approach $200 billion by 2030.
Jul 31, 2025
Eli Lilly's diabetes medication Mounjaro shows comparable heart benefits to an established treatment - STAT News
Eli Lilly's diabetes drug Mounjaro demonstrated cardiovascular benefits in a large trial, matching the performance of Trulicity. Patients on Mounjaro had an 8% lower risk of cardiovascular-related death, heart attack, or stroke compared to those on Trulicity. Additionally, Mounjaro users showed a 16% lower risk of death from any cause, though results were not statistically significant.
Jul 31, 2025
Wegovy and more: Could weight-loss medications alter perceptions of obesity?
Wegovy, the weight-loss drug by Novo Nordisk, is now available in Singapore after receiving approval from the Health Sciences Authority over two years ago. The drug, which contains the active ingredient semaglutide, is prescribed by licensed physicians. Experts discuss its implications for obesity treatment and emphasize that it is not a "magic bullet" for weight loss.
Jul 31, 2025
Obesity medications are making progress in research: Numerous clinical trials are being conducted by both large and small pharmaceutical companies.
The demand for weight-loss drugs like Wegovy (semaglutide) and Mounjaro (tirzepatide) has spurred over 170 new anti-obesity drugs in development by companies including Amgen, AstraZeneca, and Eli Lilly. Eli Lilly's orforglipron and other oral formulations are gaining attention, while Novartis and GSK remain cautious. The landscape is evolving with innovative therapies targeting various health conditions beyond obesity.
Jul 31, 2025
Novo's $60 billion decline: Hims split proves detrimental as competitors in weight loss thrive
Novo Nordisk's stock plummeted by $60 billion after ending its collaboration with Hims & Hers, amid concerns over competition in the weight-loss drug market. The company, known for Wegovy and Ozempic, has cut its sales growth forecast to 8%-14% due to rising competition from Eli Lilly's Zepbound. Novo's new CEO, Maziar Mike Doutsdar, will lead the company through these challenges.
Jul 31, 2025
A tough reality: The reasons behind rising medication costs for Americans - TRT Global
The recent US-EU trade agreement imposes a 15% tariff on EU pharmaceuticals, impacting drug prices for American consumers. Key drugs like Keytruda and Ozempic will be affected, potentially raising costs by $13-$19 billion. Pharmaceutical companies such as Sanofi, Roche, and Sandoz Group saw stock increases. The deal contrasts with the UK's more favorable terms, which include a 10% tariff.
Jul 31, 2025
Madrigal signs a $2 billion agreement for CSPC's preclinical GLP-1, focusing on the combination with Rezdiffra MASH.
Madrigal Pharmaceuticals has acquired a preclinical GLP-1 receptor agonist, SYH2086, from CSPC Pharmaceutical for $120 million, aiming to combine it with its FDA-approved fatty liver disease drug, Rezdiffra. The partnership seeks to enhance treatment efficacy for metabolic dysfunction-associated steatohepatitis (MASH). CSPC could earn up to $2 billion in milestone payments and royalties.
Jul 31, 2025
Madrigal invests in GLP-1 through CSPC; Apellis receives broader drug approval.
Madrigal Pharmaceuticals has acquired global rights to CSPC's preclinical GLP-1 drug SYH2086 for $120 million, aiming to combine it with Rezdiffra for MASH treatment. Viridian Therapeutics secured $70 million from Kissei for Japanese rights to two thyroid eye disease drugs. Apellis Pharmaceuticals' Empaveli received FDA approval for broader use, while PTC Therapeutics' Sephience was approved for phenylketonuria. Arrowhead Pharmaceuticals earned a $100 million milestone from Sarepta Therapeutics.
Jul 31, 2025
India's Struggles in Ensuring Access to Affordable Medications Amid UK Free Trade Agreement - The Federal
The Indian government's recent free trade agreement with the UK emphasizes voluntary licensing over compulsory licensing for patented medications, raising concerns about access to affordable drugs. Critics argue this shift favors multinational companies and undermines public health. Activists continue to push for compulsory licenses for life-saving drugs like Ribociclib and Abemaciclib, highlighting the need for better access to affordable medicines.
Jul 31, 2025
Rocket Science Health Obtains U.S. Patent for Targeted Intranasal Medication Delivery System
Rocket Science Health Corp. has secured U.S. Patent No. 12,343,489 for its innovative intranasal drug delivery device, aimed at enhancing targeted delivery to the brain and central nervous system. This technology could improve health outcomes by optimizing drug exposure and reducing doses. The company plans to initiate human clinical trials soon and is exploring licensing opportunities.
Jul 31, 2025
Reasons Behind Today's Decline in AbbVie Stock - The Globe and Mail
AbbVie reported a strong second quarter with revenues exceeding $15.4 billion, driven by blockbuster drugs Skyrizi and Rinvoq. However, shares dipped after President Trump demanded U.S. pharmaceutical companies, including AbbVie, reduce drug prices. AbbVie raised its 2025 profit guidance, expecting adjusted net income of $11.88 to $12.08 per share.
Jul 31, 2025
The upcoming wave of obesity medications - The Lancet Voice - iHeart
The past decade has transformed obesity treatment, with drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) leading the way in significant weight loss. However, experts are questioning if weight loss is the best measure of these drugs' effectiveness. A discussion featuring Professor Steven Heymsfield explores the advances, limitations, and societal implications of these obesity treatments.
Jul 30, 2025
Could Partnering with Bain Capital Propel BMY's Pipeline Forward? - TradingView
Bristol Myers Squibb (BMY) has partnered with Bain Capital to establish a new biopharmaceutical company focused on autoimmune therapies, with Bain investing $300 million. BMY will out-license five immunology candidates, including afimetoran and BMS-986322. BMY retains a 20% equity stake and faces competition in immunology and oncology from companies like Amgen and Merck.
Jul 30, 2025
Confrontation in Munich: Federal Patent Court annuls Xarelto patent
The Federal Patent Court revoked Bayer's patent EP 1 845 961 for rivaroxaban, used in Xarelto, due to lack of inventive step, potentially allowing generic versions to enter the German market. The court's decision, influenced by prior art from Bayer's "Einstein DVT study," raises the dispute's value to €30 million. Bayer plans to appeal, continuing its legal battles against generics.
